secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0000950170-25-088710
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health: Revita shows 92% weight maintenance post-GLP-1; Rejuva prevents obesity in mice
--------------------------------------------------------------------------------

- 12 of 13 Revita participants maintained or lost weight at 3 months after stopping GLP-1; median weight stable (0.46% change).
- No serious adverse events with Revita; REMAIN-1 Midpoint cohort data expected Q3 2025 and Pivotal cohort H2 2026.
- Rejuva single dose prevented obesity and hyperglycemia in high-fat diet mice; 20% weight reduction and 38% glucose decrease.
- Rejuva RJVA-001 progressing toward first-in-human studies; preliminary clinical data anticipated in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025088710/0000950170-25-088710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025088710/guts-20250623.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-088710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer